Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy

Journal of Clinical Virology

Volumn 13, Issue 3, 1999, Pages 149-159

  Reddy, V ^a   Hao, Y ^a   Lipton, J ^a   Meharchand, J ^a   Minden, M ^a   Mazzulli, T ^a   Chan, C ^a   Messner, H A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Bone marrow transplantation; Cytomegalovirus; Prevention

Indexed keywords

GANCICLOVIR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BRONCHOSCOPY; CYTOMEGALOVIRUS INFECTION; DONOR; ENTERITIS; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; RISK; SEROLOGY;

ADULT; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; MALE;

EID: 0032785374     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(99)00029-3     Document Type: Article

References (31)

1. Allison PD. Survival Analysis Using the SAS System: A Practical Guide, Cary, NC:SAS Institute Inc, 1995.
2. Boeckh M., Gooley T.A., Myerson D. et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double blind study. Blood. 88:1996;4063-4071.
3. Bowden R.A., Sayers M., Flournoy N. et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N. Engl. J. Med. 314:1986;1006-1010.
4. Bowden R.A., Slichter S.J., Sayers S.J. et al. Use of leukocyte depleted platelets and cytomegalovirus seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood. 78:1991;246-250.
5. Cathomas G., Marns P., Pekle K. et al. Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolar lavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells. Blood. 7:1993;1909-1914.
6. Einsele H., Ehninger G., Hebart H. et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 86:1995;2815-2820.
7. Emmanuel D., Cunningham I., Jules-Elysee K. et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high dose intravenous immune globulin. Ann. Intern. Med. 109:1988;777-782.
8. Falagas M.E., Snydman D.R., Griffith J. et al. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann. Intern. Med. 126:1997;275-279.
9. Forman S.J., Zaia J.A. Treatment and prevention of cytomegalovirus pneumonia after Bone marrow transplantation: Where do we stand? Blood. 83:1994;2392-2398.
10. Goodrich J.M., Bowden R.A., Fisher L. et al. Ganciclovir prophylaxis to prevent Cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118:1993;173-178.
11. Goodrich J.M., Motomi M., Gleaves C.A. et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N. Engl. J. Med. 325:1991;1601-1607.
12. Grob J.P., Prentice H.G., Hoffbrand A.V. et al. Immune donors can protect marrow transplant recipients from severe cytomegalovirus infections. Lancet. 1:1987;774-776.
13. Kaplan E.L., Meier P. Non parametric estimation for incomplete observations. J. Am. Stat. Assoc. 53:1985;457-481.
14. Li C.R., Greenberg P.D., Gilbert M.J. et al. Recovery of HLA restricted cytomegalovirus (CMV) specific T cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 83:1994;1971-1979.
15. Mandanas R.A., Saez R.A., Selby G. et al. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy. Am. J. Hemat. 51:1996;104-111.
16. Mazzulli T., Wood S., Chua R., Walmsley S. Evaluation of the Digene Hybrid for detection and quantitation of human cytomegalovirus viremia in human immunodeficiency virus infected patients. J. Clin. Micro. 34:1996;2959-2962.
17. Meyers J.D., Flournoy N., Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 153:1986;478-488.
18. Meyers J.D. Prevention of cytomegalovirus infection after marrow transplantation. Rev. Infect. Dis. 11:1989;1691-1705.
19. Miller W., Flynn P., McCullough J. et al. Cytomegalovirus injection after bone marrow transplantation: an association with acute graft-versus-host disease. Blood. 7:1986;1162-1167.
20. Miller W.J., McCullough J., Balfour H.H. et al. Prevention of Cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. BMT. 7:1991;227-234.
21. Przepiorka D., Ippolitic C., Panina A. et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell depleted marrow transplantation. BMT. 13:1994;461-464.
22. Reed E.C., Bowden R.A., Dandliker P.S. et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern. Med. 109:1988;783-788.
23. Schmidt G.M., Horak D.A., Niland J. et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N. Engl. J. Med. 324:1991;1005-1011.
24. Singhal S., Mehta J., Powles R. et al. Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet (letter). Blood. 84:1994;2055.
25. Singhal S., Mehta J., Powles R. et al. Three weeks of ganciclovir for cytomegaloviremia after allogeneic bone marrow transplantation. BMT. 15:1995;771-781.
26. Stover D.E., Zaman M.B., Hajdu S.I. et al. Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann. Intern. Med. 101:1984;1-7.
27. Walter E.A., Greenberg P.D., Gilbert M.J. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. New Engl. J. Med. 333:1995;1038-1044.
28. Wingard J.R. Viral infections in leukemia and bone marrow transplant patients. Leuk. Lymphoma (Suppl.). 11:1993;115-125.
29. Winston D.J., Ho W.G., Champlin R.E. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev. Infec. Dis. (Suppl.). 12:1990;776-792.
30. Winston D.J., Winston G., Ho M.D. et al. Ganciclovir prophylaxis of Cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo controlled, double blind trial. Ann. Intern. Med. 118:1993;79-84.
31. Zaia J.A., Gallez-Hawkins G.M., Tegtmeier B.R. et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J. Infect. Dis. 176:1997;782-785.